20 articles
Dasatinib + quercetin clears senescent kidney cells, restores anti-aging protein Klotho, and reverses transcriptional aging across multiple renal cell types.
Senescent endothelial cells that accumulate after bone injury sabotage stem cell repair — and quercetin delivered locally can reverse this.
A senolytic pairing of dasatinib and quercetin cleared senescent cells at the tendon-bone junction, dramatically improving repair strength in aged rats.
Discover how revolutionary drugs target 'zombie cells' that accumulate with age, potentially reversing aging and extending healthspan.
ProcyanidinC1, a natural senolytic, selectively eliminates senescent cells in diabetic skin, dramatically improving wound healing in mouse models.
A novel anti-swelling hydrogel loaded with dasatinib, quercetin, and nucleus pulposus exosomes clears senescent cells and restores disc integrity in rats and goats.
A novel photoactivatable drug system uses NK immune cells to eliminate aging joint cells, reducing osteoarthritis progression in mice.
New review reveals how plant-based compounds and stem cell therapies could eliminate aging cells and restore youthful function.
Explore the molecular mechanisms of cellular senescence and how p16/p21 pathways drive SASP production, plus cutting-edge senolytic drug targets.
Novel iodide-enhanced hydrogel penetrates gum pockets to eliminate harmful bacteria while protecting regenerative stem cells.
Single-cell sequencing reveals ferroptosis drives pulpitis; thymosin α1 restores GPX4, cuts iron overload, and reduces inflammation in cells and rats.
Novel nanogel therapy targets mitochondrial ROS to break the inflammation-hypoxia cycle in periodontitis, showing strong preclinical results.
A short-term drug combo rejuvenates aged mesenchymal stem cells, boosting proliferation and reducing inflammatory markers in vitro.
A sweeping review maps every known strategy for delivering therapies directly to mitochondria, from lifestyle habits to nanocarriers and gene editing.
Scientists discover how tumors use glucose to survive lysosome-blocking drugs, revealing promising combination therapies.
Master the cutting-edge molecular targets, clinical trial data, and emerging therapeutic strategies aimed at reversing ECM aging — from senolytic combinations to biomaterial scaffolds and epigenetic reprogramming.
A pharmacological cocktail transiently activates reprogramming genes in senescent endothelial cells, restoring function and improving blood flow in aged mice.
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
A novel class of ferroptosis inhibitors protects donor organs from ischemia-reperfusion injury, potentially saving thousands of transplant patients annually.
A new class of drugs called proximity degraders can destroy disease-causing proteins once considered untreatable. Here's what's coming next.
